Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[18F]PT2385 PET/CT in Renal Cell Carcinoma
NCT04989959Phase 1Recruiting
- Start
- Aug 2021
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of [18F]PT2385 in renal cell carcinoma (RCC) and von Hippel-Lindau syndrome (VHL) (3 arms). Primary endpoints: Correlation between [18F]PT2385 and HIF2α up to 5 years and Correlation between [18F]PT2385 and HIF2α Immunohistochemistry up to 5 years. Started Aug 2021; status: recruiting.
02
Drugs
[18F]PT2385
03
Conditions
renal cell carcinoma (RCC)von Hippel-Lindau syndrome (VHL)
Beyond the preview
Go deeper on NCT04989959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04989959.